PharmaTimes | Industry News | World News | …although generics batter GSK fourth-quarter pharma sales: "Amid all the talk of job losses, GlaxoSmithKline’s fourth-quarter financials revealed a 4% decline in pharmaceutical sales to £5.80 billion, hit again by generic competition and lower revenues of the diabetes drug Avandia.
Sales of Avandia (rosiglitazone) were down 24% to £147 million, while generic competition in the USA hit its central nervous system drugs hard. Revenues from Paxil/Seroxat (paroxetine) fell 21% to $154 million, while another antidepressant, Wellbutrin (bupropion), slumped 63% to £66 million."
http://www.pharmatimes.com/WorldNews/article.aspx?id=15263
No comments:
Post a Comment
Note: only a member of this blog may post a comment.